Structure-based lead identification of ATP-competitive MK2 inhibitors.
SourceBioorganic & Medicinal Chemistry Letters, 21, 12, (2011), pp. 3818-3822
Article / Letter to editor
Display more detailsDisplay less details
Laboratory of Clinical Chemistry
Bioorganic & Medicinal Chemistry Letters
SubjectN4i 4: Auto-immunity, transplantation and immunotherapy
MK2 kinase is a promising drug discovery target for the treatment of inflammatory diseases. Here, we describe the discovery of novel MK2 inhibitors using X-ray crystallography and structure-based drug design. The lead has in vivo efficacy in a short-term preclinical model.
Upload full text